Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.

Aberrant expression of beta-tubulin isotypes is frequently described in tumor tissues and tubulin-binding agent (TBA)-resistant cell lines. There is limited understanding of the role of specific beta-tubulin isotypes in cellular sensitivity to TBAs, and to gain insights into the functional role of betaII- and betaIVb-tubulin, we examined these isotypes in lung cancer cell lines NCI-H460 (H460) and Calu-6. Drug-treated clonogenic assays revealed that small interfering RNA-mediated knockdown of either betaII- or betaIVb-tubulin hypersensitized the lung cancer cell lines to Vinca alkaloids, with the effects more pronounced following betaIVb-tubulin knockdown. In contrast, there was no change in paclitaxel sensitivity following knockdown of either isotype. Cell cycle analysis revealed a greater propensity for the betaII- and betaIVb-tubulin knockdown cells to undergo G2-M cell cycle block following 5 nmol/L vincristine treatment, with the betaIVb knockdown cells being more sensitive than the betaII-tubulin knockdown cells compared with control. In contrast to betaII-tubulin knockdown, betaIVb-tubulin knockdown cells showed a significant increase in the sub-G1 population (cell death) following treatment with both 5 and 40 nmol/L of vincristine compared with controls. Importantly, betaIVb-tubulin knockdown in H460 cells caused a significant dose-dependent increase in Annexin V staining in response to vincristine but not paclitaxel. Therefore, increased sensitivity to induction of apoptosis is one mechanism underlying the Vinca alkaloid hypersensitivity. This study provides direct evidence that betaII- or betaIVb-tubulins have functionally distinct roles and expression of these isotypes may serve as strong predictors of Vinca alkaloid response and resistance.

[1]  R. Luduena,et al.  Removal of beta III isotype enhances taxol induced microtubule assembly. , 1993, Cell structure and function.

[2]  M. Kavallaris,et al.  The role of β-tubulin isotypes in resistance to antimitotic drugs , 2001 .

[3]  A. Frankfurter,et al.  b-Tubulin Isotype Classes II and V Expression Patterns in Nonsmall Cell Lung Carcinomas , 2008 .

[4]  I. Brown,et al.  The FASEB Journal express article 10.1096/fj.04-3178fje. Published online June 9, 2005. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel , 2022 .

[5]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[6]  R. Luduena,et al.  Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. , 1990, The Journal of biological chemistry.

[7]  T. Fojo,et al.  Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  C. Dumontet,et al.  Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? , 2008, The Lancet. Oncology.

[9]  M. Kavallaris,et al.  Microtubule alterations and resistance to tubulin-binding agents (review). , 2002, International journal of oncology.

[10]  P. Hains,et al.  Proteome Analysis of Vinca Alkaloid Response and Resistance in Acute Lymphoblastic Leukemia Reveals Novel Cytoskeletal Alterations* , 2003, Journal of Biological Chemistry.

[11]  E. Nogales Structural insights into microtubule function. , 2000, Annual review of biochemistry.

[12]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[13]  N. Wake,et al.  Expression of beta-tubulin isotypes in human primary ovarian carcinoma. , 2007, Gynecologic oncology.

[14]  A. Frankfurter,et al.  β class II tubulin predominates in normal and tumor breast tissues , 2003, Breast Cancer Research.

[15]  R. Luduena Multiple forms of tubulin: different gene products and covalent modifications. , 1998, International review of cytology.

[16]  A. Frankfurter,et al.  Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity. , 1998, Cell motility and the cytoskeleton.

[17]  W. B. Derry,et al.  Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. , 1997, Biochemistry.

[18]  J. Correia,et al.  A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. , 1998, Molecular pharmacology.

[19]  D. Panda,et al.  Microtubule dynamics in vitro are regulated by the tubulin isotype composition. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Hailing Yang,et al.  Heightened Sensitivity to Paclitaxel in Class IVa β-Tubulin-transfected Cells Is Lost as Expression Increases* , 2007, Journal of Biological Chemistry.

[21]  Anthony Frankfurter,et al.  Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas. , 2008, Cell motility and the cytoskeleton.

[22]  M. Kavallaris,et al.  The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities. , 2007, Current Drug Targets.

[23]  M. Kavallaris,et al.  Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. , 2005, Current pharmaceutical design.

[24]  B. Sikic,et al.  Differential expression of tubulin isotypes during the cell cycle. , 1996, Cell motility and the cytoskeleton.

[25]  J. Wolff,et al.  Localization of the vinblastine-binding site on beta-tubulin. , 1996, The Journal of biological chemistry.

[26]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Banerjee Increased levels of tyrosinated α-, βIII-, and βIV-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells , 2002 .

[28]  D. Larsimont,et al.  Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. , 2002, Clinical breast cancer.

[29]  B. Sikic,et al.  Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. , 1995, Oncology research.

[30]  D. Menick,et al.  Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. , 1999, Journal of cell science.

[31]  G. Hudes,et al.  Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. , 1998, British Journal of Cancer.

[32]  Susan Band Horwitz,et al.  Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.

[33]  F. Wang,et al.  Detection of human betaV-tubulin expression in epithelial cancer cell lines by tubulin proteomics. , 2005, Biochemistry.

[34]  M. Haber,et al.  Altered Expression of M2, the Class II -Tubulin Isotype, in a Murine J774.2 Cell Line with a High Level of Taxol Resistance (*) , 1995, The Journal of Biological Chemistry.

[35]  E. Pasquier,et al.  Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer , 2007 .

[36]  K. Tew,et al.  Increase of βIII- and βIVa-Tubulin Isotypes in Human Prostate Carcinoma Cells as a Result of Estramustine Resistance , 1996 .

[37]  M. Kavallaris,et al.  Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. , 2001, Cancer research.

[38]  P. Gunning,et al.  Alterations in γ-Actin and Tubulin-Targeted Drug Resistance in Childhood Leukemia , 2006 .